Sohrab Shah, PhD

Chief of Computational Oncology; Nicholls-Biondi Chair
Epidemiology & Biostatistics
Directory
Epidemiology
Biostatistics
Health Outcomes
Computational Oncology
Administrative Resources
Career Opportunities
Educational Opportunities
Departmental Newsletter

Sohrab Shah, PhD

Chief of Computational Oncology; Nicholls-Biondi Chair
Share
Share
Sohrab Shah

Office Phone

646-608-7558

Email

[email protected]

URL

View Sohrab Shah’s Lab

Dr. Shah is the Chief of Computational Oncology in the Department of Epidemiology and Biostatistics. His laboratory studies tumor evolution - primarily in genomically unstable cancers.  This encompasses uncovering the root causes of tumor initiation, drug resistance and metastasis through single cell approaches, computational modeling and the theoretical principles of evolution. His lab has pioneered computational methods and single cell technologies to enable advances in understanding drug resistance, immune selective pressures and mutational processes - primarily in breast and ovarian cancer. In addition, since joining MSK he has led a new program in analyzing real-world data from patients including clinical genomics, digital pathology and radiology with AI and machine learning methods to develop predictive models for personalized medicine. Dr. Shah is a former Canada Research Chair, is a Susan G. Komen Scholar, and holds the Nicholls-Biondi Endowed Chair in Computational Oncology at MSK.

Publications

  1. Vázquez-García, I., Uhlitz, F., Ceglia, N. … Shah SP. Ovarian cancer mutational processes drive site-specific immune evasion. Nature 2022; 612(7941):778-786. PMCID: PMC9771812.
  2. Funnell T*, O’Flanagan C*, Williams M*, … Shah SP, Aparicio S. Single cell genomic variation induced by mutational processes in cancer. Nature 2022; 612(7938):106-115. PMCID: PMC9712114.
  3. Salehi S, Kabeer F, Ceglia N, Andronescu M, Williams MJ,  … Shah SP. Clonal fitness inferred from time-series modelling of single-cell cancer genomes. Nature. 2021 Jul;595(7868):585-590. doi: 10.1038/s41586-021-03648-3. Epub 2021 Jun 23. PMID: 34163070; PMCID: PMC8396073.
  4. Boehm KM, Aherne EA, Ellenson L, … Shah SP. Multimodal data integration using machine learning improves risk stratification of high-grade serous ovarian cancer. Nat Cancer. 2022 (6):723-733. PMCID: PMC9239907.
  5. Vanguri RS, Luo J, Aukerman AT, … Shah SP. Multimodal integration of radiology, pathology and genomics for prediction of response to PD-(L)1 blockade in patients with non-small cell lung cancer. Nat Cancer. 2022 (10):1151-1164. PMCID: PMC9586871.
  6. Laks E, Zahn H, Lai D, McPherson A, Steif A,… Shah SP, Aparicio S. Clonal Decomposition and DNA Replication States Defined by Scaled Single-Cell Genome Sequencing Cell. 2019;179(5):1207-1221.e22. PMCID: PMC6912164.
  7. Zhang AW… Shah SP. Probabilistic cell-type assignment of single-cell RNA-seq for tumor microenvironment profiling. Nat Methods. 2019;16(10):1007-15. PMCID: PMC7485597

 

View a complete listing of Sohrab Shah’s publications

My Pages

My Videos

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Sohrab Shah discloses the following relationships and financial interests:

  • AstraZeneca
    Professional Services and Activities
  • Imagia Canexia Health Inc.
    Equity

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].


View all disclosures

Related topics: